Sanford C. Bernstein Begins Coverage on Medline (NASDAQ:MDLN)

Analysts at Sanford C. Bernstein initiated coverage on shares of Medline (NASDAQ:MDLN) in a report issued on Monday, Marketbeat reports. The brokerage set an “outperform” rating and a $49.00 price target on the stock. Sanford C. Bernstein’s price target points to a potential upside of 14.35% from the company’s previous close.

A number of other research firms have also issued reports on MDLN. Piper Sandler assumed coverage on shares of Medline in a research report on Monday. They set an “overweight” rating and a $50.00 price target on the stock. Leerink Partners started coverage on shares of Medline in a research note on Monday. They set an “outperform” rating and a $48.00 target price on the stock. William Blair started coverage on shares of Medline in a research note on Monday. They issued an “outperform” rating for the company. BNP Paribas initiated coverage on shares of Medline in a research report on Monday. They set a “neutral” rating and a $38.00 price target on the stock. Finally, BNP Paribas Exane began coverage on Medline in a research report on Monday. They issued a “neutral” rating and a $38.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $46.70.

Medline Trading Up 0.3%

Medline stock opened at $42.85 on Monday. Medline has a 12 month low of $34.89 and a 12 month high of $45.50.

Insider Buying and Selling at Medline

In other Medline news, major shareholder Hellman & Friedman Capital Par sold 6,088,371 shares of the stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $28.37, for a total value of $172,727,085.27. Following the transaction, the insider directly owned 4,806,160 shares in the company, valued at $136,350,759.20. This represents a 55.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Charles N. Mills acquired 2,579,310 shares of the firm’s stock in a transaction on Thursday, December 18th. The stock was bought at an average price of $29.00 per share, with a total value of $74,799,990.00. Following the purchase, the director directly owned 2,441,379 shares of the company’s stock, valued at $70,799,991. This represents a -1,870.00% increase in their ownership of the stock. The SEC filing for this purchase provides additional information.

Key Stories Impacting Medline

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Many major firms launched coverage with buy/overweight or strong‑buy ratings and targets clustered between $45 and $52, citing durable growth, margin expansion and a prime‑vendor advantage — this broad analyst stamp is the main driver of the rally today. TipRanks: Surge on analyst buy notes
• Positive Sentiment: Truist initiated coverage with a Buy and a $52 target (the highest among recent initiations), highlighting upside of ~20% vs. the current level — a concrete high‑target call that supports upside momentum. The Fly: Truist initiation
• Positive Sentiment: Analysts point to Medline’s scale (Jefferies highlights a ~$25bn supply‑chain footprint), vertical integration and branded‑mix shift as catalysts for margin expansion — fundamental reasons underpin many buy ratings. Yahoo Finance: Jefferies coverage
• Positive Sentiment: Medline’s IPO raised roughly $7 billion and the stock’s strong market debut has drawn Wall Street attention; post‑IPO liquidity and fresh research coverage are amplifying buying interest. NAI500: Market debut coverage
• Neutral Sentiment: Reported short interest figures are effectively zero/immaterial in the published data, so there’s no visible short‑squeeze signal backing the move — the rally appears driven by buy‑side interest and research coverage. (internal data)
• Negative Sentiment: Not all research is bullish: BNP Paribas put a neutral $38 target (implying downside), and Deutsche Bank issued a hold with a $40 target — these lower targets provide resistance for longer‑term upside and could cap gains if investors focus on valuation. Benzinga: Coverage summary
• Negative Sentiment: Wells Fargo’s equal‑weight $42 target and other neutral/hold calls (Rothschild/Rothschild Redburn) highlight mixed views on near‑term valuation — expect greater sensitivity to execution and margin guidance in coming quarters. Zacks: Analyst initiations

About Medline

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.